Physician profile
Anthony Gordon
NPI 1912968041
$8,747.94
in general payments reported to CMS, 2019-2025
10 companies · $51.18 in 2025
The $51.18 reported for 2025 was less than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $17.94 · 2021: $553 · 2022: $523 · 2023: $186 · 2024: $7,297 · 2025: $51.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $7,068 · Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $7,068.00 |
| Food and Beverage | $466.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $7,068.00 | 2024 | |
| Kerecis Limited | $585.82 | 2021-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $453.31 | 2020-2022 | |
| Organogenesis INC. | $236.40 | 2021 | |
| Koya Medical, INC. | $166.18 | 2024 | Dayspring, Koya Medical |
| Osiris Therapeutics INC. | $120.38 | 2019 | |
| Novo Nordisk INC | $40.64 | 2022-2023 | Ozempic, Rybelsus |
| Integra Lifesciences Corporation | $28.28 | 2023 | Durasorb Monofilament Mesh |
| Bioventus LLC | $25.46 | 2022 | |
| Abbvie INC. | $23.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.